



- (51) **International Patent Classification:**
C12N 15/861 (2006.01) A61P 25/00 (2006.01)
- (21) **International Application Number:**
PCT/US2024/029507
- (22) **International Filing Date:**
15 May 2024 (15.05.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/466,598 15 May 2023 (15.05.2023) US
63/606,012 04 December 2023 (04.12.2023) US
- (71) **Applicant:** SANGAMO THERAPEUTICS, INC.
[US/US]; 501 Canal Blvd., Suite A100, Richmond, California 94804 (US).
- (72) **Inventors:** TIFFANY, Matthew; c/o Sangamo Therapeutics, Inc., 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). OJALA, David; c/o Sangamo Therapeutics, Inc., 501 Canal Blvd., Suite A100, Richmond, California 94804 (US).
- (74) **Agent:** WURSTER, April; 1 East Washington Street, Suite 2700, Phoenix, Arizona 85004 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) **Title:** ENGINEERED BLOOD BRAIN BARRIER PENETRANT AAV CAPSIDS




FIG. 1

(57) **Abstract:** This application relates to engineering AAV capsids. In some embodiments, the engineered AAV capsids are capable of penetrating the blood brain barrier and transducing cells in the central nervous system.